Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies

Table 2

Ongoing trials with anti-PD-L1 in advanced gastric cancer.

Study ID	Study phase	Treatment	Population	Status
YO39609; (NCT03281369)	I/II	Multiple immunotherapy-based treatment combinations, including atezolizumab as immunotherapeutic agent	Patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer	Recruiting
JAVELIN Gastric 300; (NCT02625623)	III	Avelumab + best supportive care (BSC) versus physician's choice chemotherapy + BSC or BSC alone	Unresectable, recurrent, locally advanced, or metastatic gastric or gastroesophageal junction adenocarcinoma gastric cancer third line	Active, not recruiting
JAVELIN Gastric 100; (NCT02625610)	III	Avelumab (MSB0010718C) versus continuation of first-line chemotherapy	Unresectable, locally advanced, or metastatic adenocarcinoma of the stomach or of the gastroesophageal junction	Active, not recruiting
JAVELIN MEDLEY; (NCT02554812)	Ib/II	Avelumab (MSB0010718C) in combination with other cancer immunotherapies	Patients with locally advanced or metastatic solid tumors	Recruiting
MEDIOLA; (NCT02734004)	I/II	MEDI4736 in combination with olaparib	Patients with advanced solid tumors, selected based on a rationale for response to olaparib	Active, not recruiting
I4T-MC-JVDJ; (NCT02572687)	I	Ramucirumab plus MEDI4736	Participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small-cell lung cancer (NSCLC) or hepatocellular carcinoma (HCC)	Active, not recruiting
PLATFORM; (NCT02678182)	II	Maintenance therapies following completion of standard first-line chemotherapy: placebo versus capecitabine versus durvalumab versus trastuzumab versus rucaparib	Patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophagogastric adenocarcinomas	Recruiting
D419SC00001; (NCT02658214)	Ib	Durvalumab and tremelimumab in combination with first-line chemotherapy	Patients with advanced solid tumors	Recruiting

MEDI4736 also known as durvalumab.